In addition, the effect of canagliflozin, an SGLT-1 and SGLT-2 co-inhibitor, on BMD and bone fracture may be associated with the oversuppression of both SGLT-1 and SGLT-2, but other SGLT-2is only act on SGLT-2. This evidence concerns the gene SLC5A2 and bone fracture.